Theoretical considerations on quantitative prediction of drug-drug interactions

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 1, 2010, Pages 48-61

  Hisaka, Akihiro ^a   Ohno, Yoshiyuki ^a   Yamamoto, Takehito ^a   Suzuki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Clinical pharmacokinetics; Cytochrome p450; Drug metabolism; Drug drug interaction; In vitro in vivo extrapolation; Pharmacokinetics; Physiological pharmacokinetics

Indexed keywords

ALPRAZOLAM; ATORVASTATIN; AZITHROMYCIN; BUSPIRONE; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; FELODIPINE; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; GATIFLOXACIN; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIDAZOLAM; NEFAZODONE; NISOLDIPINE; RANITIDINE; ROXITHROMYCIN; SIMVASTATIN; TELITHROMYCIN; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL; VORICONAZOLE; XENOBIOTIC AGENT; ZOLPIDEM;

AREA UNDER THE CURVE; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENTIATION; ENZYME METABOLISM; GRAPEFRUIT JUICE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER BLOOD FLOW; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PREDICTION; REVIEW; URINARY EXCRETION;

EID: 77949300138     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.48     Document Type: Review

References (69)

1. Egger, S. S., Drewe, J. and Schlienger, R. G.: Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur. J. Clin. Pharmacol., 58: 773-738 (2003).
2. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J. et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ, 329: 15-19 (2004).
3. Rogers, J. F., Nafziger, A. N. and Bertino, J. S., Jr.: Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am. J. Med., 113: 746-750 (2002).
4. Rendic, S. and Di Carlo, F. J.: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev., 29: 413-580 (1997).
5. Furberg, C. D. and Pitt, B.: Withdrawal of cerivastatin from the world market. Curr. Control Trials Cardiovasc. Med., 2: 205-207 (2001).
6. Okuda, H., Nishiyama, T., Ogura, K., Nagayama, S., Ikeda, K., Yamaguchi, S. et al.: Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab. Dispos., 25: 270-273 (1997).
7. Yan, Z. and Caldwell, G. W.: Metabolism profiling, and cytochrome P450 inhibition and induction in drug discovery. Curr. Top. Med. Chem., 1: 403-425 (2001).
8. Baranczewski, P., Stanczak, A., Sundberg, K., Svensson, R., Wallin, A., Jansson, J. et al.: Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol. Rep., 58: 453-472 (2006).
9. Grime, K. H., Bird, J., Ferguson, D. and Riley, R. J.: Mechanismbased inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur. J. Pharm. Sci., 36: 175-191 (2009).
10. Thelen, K. and Dressman, J. B.: Cytochrome P450-mediated metabolism in the human gut wall. J. Pharm. Pharmacol., 61: 541-558 (2009).
11. Yang, J., Tucker, G. T. and Rostami-Hodjegan, A.: Cytochrome P450 3A expression and activity in the human small intestine. Clin. Pharmacol. Ther., 76: 391 (2004).
12. Lin, J. H. and Lu, A. Y.: Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet., 35: 361-390 (1998).
13. Dresser, G. K., Spence, J. D. and Bailey, D. G.: Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet., 38: 41-57 (2000).
14. Houston, J. B. and Galetin, A.: Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr. Drug Metab., 9: 940-951 (2008).
15. Bertz, R. J. and Granneman, G. R.: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet., 32: 210-258 (1997).
16. Shou, M.: Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Curr. Opin. Drug Discov. Devel., 8: 66-77 (2005).
17. Fowler, S. and Zhang, H.: In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J., 10: 410-424 (2008).
18. Ohno, Y., Hisaka, A. and Suzuki, H.: General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin. Pharmacokinet., 46: 681-696 (2007).
19. Ohno, Y., Hisaka, A., Ueno, M. and Suzuki, H.: General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin. Pharmacokinet., 47: 669-680 (2008).
20. Wienkers, L. C. and Heath, T. G.: Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov., 4: 825-833 (2005).
21. Ito, K., Brown, H. S. and Houston, J. B.: Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br. J. Clin. Pharmacol., 57: 473-486 (2004).
22. Brown, H. S., Galetin, A., Hallifax, D. and Houston,: J. B. Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin. Pharmacokinet., 45: 1035-1050 (2006).
23. Yang, J., Jamei, M., Yeo, K. R., Tucker, G. T. and Rostami-Hodjegan, A.: Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab., 8: 676-684 (2007).
24. Ahmad, A. B., Bennett, P. N. and Rowland, M.: Models of hepatic drug clearance: discrimination between the 'well stirred' and 'parallel-tube' models. J. Pharm. Pharmacol., 35: 219-224 (1983).
25. Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H. and Sugiyama, Y.: Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev., 50: 387-412 (1998).
26. Venkatakrishnan, K., Obach, R. S. and Rostami-Hodjegan, A.: Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica, 37: 1225-1256 (2007).
27. Hollenberg, P. F., Kent, U. M. and Bumpus, N. N.: Mechanismbased inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem. Res. Toxicol., 21: 189-205 (2008).
28. Hisaka, A., Ohno, Y., Yamamoto, T. and Suzuki, H.: Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol. Ther., 125: 230-248 (2010).
29. Ito, K., Hallifax, D., Obach, R. S. and Houston, J. B.: Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab. Dispos., 33: 837-844 (2005).
30. Fujita, K.: Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol. Drug Interact., 20: 195-217 (2004).
31. Guengerich, F. P.: Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann. Rev. Phmacol. Toxicol., 39: 1-17 (1999).
32. Wrighton, S. A. and Stevens, J. C.: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol., 22: 1-21 (1992).
33. Obach, R. S., Walsky, R. L. and Venkatakrishnan, K.: Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos., 35: 246-255 (2007).
34. Giusti, D. L. and Hayton, W. L.: Dosage regimen adjustments in renal impairment. Drug Intell. Clin. Pharm., 7: 382-387 (1973).
35. Huang, S. M., Temple, R., Throckmorton, D. C. and Lesko, L. J.: Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther., 81: 298-304 (2007).
36. Hisaka, A., Kusama, M., Ohno, Y., Sugiyama, Y. and Suzuki, H.: A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling. Clin. Pharmacokinet., 48: 653-666 (2009).
37. Newton, D. J., Wang, R. W. and Lu, A. Y.: Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos., 23: 154-158 (1995).
38. Rodrigues, A. D.: Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. pharmacol., 57: 465-480 (1999).
39. Tucker, G. T., Houston, J. B. and Huang, S. M.: Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus. Pharm. Res., 18: 1071-1080 (2001).
40. McGinnity, D. F., Parker, A. J., Soars, M. and Riley, R. J.: Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab. Dispos., 28, 1327-34 (2000).
41. Uttamsingh, V., Lu, C., Miwa, G. and Gan, L. S.: Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab. Dispos., 33: 1723-1728 (2005).
42. Kobayashi, K., Chiba, K., Yagi, T., Shimada, N., Taniguchi, T., Horie, T. et al.: Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J. Pharmacol. Exp. Ther., 280: 927-933 (1997).
43. Nakajima, M., Nakamura, S., Tokudome, S., Shimada, N., Yamazaki, H. and Yokoi, T.: Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab. Dispos., 27: 1381-1391 (1999).
44. Crespi, C. L.: Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. In Testa, B. and Meyer, U. S. (ed.): Advances in Drug Research 26 ed, London, Academic Press, 1995, pp. 179-235.
45. Shitara, Y., Horie, T. and Sugiyama, Y.: Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci., 27: 425-446 (2006).
46. Endres, C. J., Hsiao, P., Chung, F. S. and Unadkat, J. D.: The role of transporters in drug interactions. Eur. J. Pharm. Sci., 27: 501-517 (2006).
47. Tsuji, A.: Impact of transporter-mediated drug absorption, distribution, elimination and drug interactions in antimicrobial chemotherapy. J. Infect, Chemother., 12: 241-250 (2006).
48. Kindla, J., Fromm, M. F. and Konig, J.: In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug inter-actions. Expert Opin. Drug Metab. Toxicol., 5: 489-500 (2009).
49. Doherty, M. M. and Charman, W. N.: The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin. Pharmacokinet., 41: 235-253 (2002).
50. Kolars, J. C., Awni, W. M., Merion, R. M. and Watkins, P. B.: First-pass metabolism of cyclosporin by the gut. Lancet, 338: 1488-1490 (1991).
51. Thummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D. et al.: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther., 59: 491-502 (1996).
52. Edgar, B., Bailey, D., Bergstrand, R., Johnsson, G. and Regardh, C. G.: Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine-and its potential clinical relevance. Eur. J. Clin. Pharmacol., 42: 313-317 (1992).
53. Kupferschmidt, H. H., Ha, H. R., Ziegler, W. H., Meier, P. J. and Krahenbuhl, S.: Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther., 58: 20-28 (1995).
54. Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L. et al.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther., 283: 1552-1562 (1997).
55. Galetin, A. and Houston, J. B.: Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J. Pharmacol. Exp.Ther., 318: 1220-1229 (2006).
56. Kato, M.: Intestinal first-pass metabolism of CYP3A4 substrates. Drug. Metab. Pharmacokinet., 23: 87-94 (2008).
57. Galetin, A., Hinton, L. K., Burt, H., Obach, R. S. and Houston, J. B.: Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr. Drug Metab., 8: 685-693 (2007).
58. Kato, M., Chiba, K., Hisaka, A., Ishigami, M., Kayama, M., Mizuno, N. et al.: The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab. Pharmacokinet., 18: 365-372 (2003).
59. Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B. and Tremaine, L. M.: The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther., 316: 336-348 (2006).
60. Rostami-Hodjegan, A. and Tucker, G. T.: Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov., 6: 140-148 (2007).
61. Kimura, T. and Higaki, K.: Gastrointestinal transit and drug absorption. Biol. Pharm. Bull., 25: 149-164 (2002).
62. Willmann, S., Lippert, J. and Schmitt, W.: From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin. Drug Metab. Toxicol., 1: 159-168 (2005).
63. Jamei, M., Turner, D., Yang, J., Neuhoff, S., Polak, S., Rostami-Hodjegan, A. et al.: Population-based mechanistic prediction of oral drug absorption. AAPS J., 11: 225-237 (2009).
64. Faller, B.: Artificial membrane assays to assess permeability. Curr. Drug Metab., 9: 886-892 (2008).
65. van Breemen, R.B. and Li, Y.: Caco-2 cell permeability assays to measure drug absorption. Expert Opin. Drug Metab. Toxicol., 1: 175-185 (2005).
66. Avdeef, A.: The rise of PAMPA. Expert Opin. Drug Metab. Toxicol., 1: 325-342 (2005).
67. Press, B. and Di Grandi, D.: Permeability for intestinal absorption: Caco-2 assay and related issues. Curr. Drug Metab., 9: 893-900 (2008).
68. Niwa, T., Shiraga, T. and Takagi, A.: Drug-drug interaction of antifungal drugs. Yakugaku Zashi., 125: 795-805 (2005).
69. Galetin, A., Ito, K., Hallifax, D. and Houston J. B.: CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J. Pharmacol. Exp. Ther., 314: 180-190 (2005).